Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization For Setmelanotide For Use In Patients With Hypothalamic Obesity In France
Portfolio Pulse from Happy Mohamed
Rhythm Pharmaceuticals (NASDAQ:RYTM) has received pre-marketing early access authorization AP1 for its drug setmelanotide in France. The drug is intended for patients with hypothalamic obesity, a rare form of obesity caused by damage to the hypothalamic region of the brain. The AP1 allows for early access to innovative therapies prior to European regulatory approval. The drug has been available through a similar program for patients with Bardet-Biedl syndrome since July 2022.
August 07, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals' stock may see a positive impact due to the early access authorization for setmelanotide in France. This could potentially increase the company's revenue and market presence in Europe.
The early access authorization for setmelanotide in France allows Rhythm Pharmaceuticals to provide the drug to patients before it receives regulatory approval. This could potentially increase the company's revenue and market presence in Europe, which could positively impact the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100